Literature DB >> 17355950

Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.

L Taillade1, F Penault-Llorca, T Boulet, P Fouret, S Michiels, E Taranchon, G Mountzios, P Validire, J Domont, P Girard, D Grunenwald, T Le Chevalier, J-C Soria.   

Abstract

BACKGROUND: The increasing use of biomarkers as molecular determinants of responsiveness to conventional chemotherapy or molecular targeted therapy has raised the question of the reliability and reproducibility of their evaluation in bronchial biopsies as compared with corresponding resected surgical specimens. PATIENTS AND METHODS: Immunohistochemical expression of five markers related to signal transduction [epidermal growth factor receptor (EGFR), phospho-Akt], cell proliferation (Ki-67), DNA repair [excision repair cross-complementing (ERCC)1] and cellular 'immortality' [human telomerase catalytic component (hTERT)], was assessed in 41 patients with operable non-small-cell lung cancer in both bronchial biopsies and whole surgical specimens.
RESULTS: High correlation coefficients were observed between the expression of ERCC1, hTERT and Ki-67 in the biopsies and the surgical specimens [0.83 (P < 0.0001); 0.55 (P < 0.001) and 0.64 (P < 0.0001), respectively]. On the other hand, biomarker expression in biopsy was less correlated with the expression in the whole tissue sample for the markers of signal response and transduction [0.24 (P = 0.17) and 0.29 (P = 0.09) for EGFR and phospho-Akt, respectively].
CONCLUSIONS: Our results indicate a lack of association in the expression of important biomarkers between lung biopsies and corresponding resected tumors, with discordance rates ranging between 9% and 41%. Although these results need to be further validated in larger cohorts, they indicate that the evaluation of the expression of biomarkers in bronchial biopsies can be misleading.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355950     DOI: 10.1093/annonc/mdm072

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  19 in total

1.  Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.

Authors:  Yalei Zhang; Haihong Yang; Yuan Qiu; Qiuhua Deng; Jun Liu; Meiling Zhao; Ping He; Mingcong Mo; Xusen Zou; Jianxing He
Journal:  Med Oncol       Date:  2014-01-23       Impact factor: 3.064

Review 2.  The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.

Authors:  Vesna Bišof; Matea Zajc Petranović; Zoran Rakušić; Kristina Ruža Samardžić; Antonio Juretić
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-16       Impact factor: 2.503

3.  Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.

Authors:  Jan Nyrop Jakobsen; Eric Santoni-Rugiu; Jens Benn Sørensen
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-23       Impact factor: 4.553

4.  Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.

Authors:  Vesna Bišof; Antonija Jakovčević; Sven Seiwerth; Zoran Rakušić; Slavko Gašparov
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-26       Impact factor: 4.553

5.  ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer.

Authors:  Nurhan Bilen; Salim B Tekin; Omer Topdagi
Journal:  Eurasian J Med       Date:  2014-06

6.  ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Authors:  Matthias Villalobos; Piotr Czapiewski; Niels Reinmuth; Jürgen R Fischer; Stefan Andreas; Cornelius Kortsik; Monika Serke; Martin Wolf; Petra Neuser; Alexander Reuss; Philipp A Schnabel; Michael Thomas
Journal:  Med Oncol       Date:  2018-06-15       Impact factor: 3.064

7.  Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

Authors:  Fred R Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; Dinah V Parums; Georgina Speake; Brian Holloway; Paul A Bunn; Wilbur A Franklin
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

Review 8.  From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

Authors:  A Thomas; A Rajan; A Lopez-Chavez; Y Wang; G Giaccone
Journal:  Ann Oncol       Date:  2012-11-06       Impact factor: 32.976

9.  Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues.

Authors:  Janine A Burns; Yuan Li; Carol A Cheney; Yangsi Ou; Laura L Franlin-Pfeifer; Nelly Kuklin; Zhi-Qiang Zhang
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

10.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Authors:  Alec Vaezi; Chelsea H Feldman; Laura J Niedernhofer
Journal:  Pharmgenomics Pers Med       Date:  2011-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.